Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index; 18 of the 26 sources its claims cite were checked for support.

Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series

Open access
Tinsley, Grant M., Nadolsky, Spencer · 2025 · SAGE Open Medical Case Reports

Abstract

GLP-1 receptor agonists (e.g., semaglutide) and dual GLP-1/GIP receptor agonists (e.g., tirzepatide) are effective for reducing body weight and fat mass, though lean soft tissue loss comprised 26%–40% of weight loss in recent trials. This case series describes three patients (two female, one male; body mass index: 32.9–51.9 kg m −2 ) who prioritized lean soft tissue preservation strategies during treatment with semaglutide or tirzepatide. Patients engaged in intentional exercise or structured physical activity 4–7 days·week −1 , including resistance training 3–5 days·week −1 . Typical protein intakes were 0.7–1.7 g·kg −1 ·day −1 relative to body mass and 1.6–2.3 g·kg −1 ·day −1 relative to fat-free mass. Changes in weight, fat mass, and lean soft tissue were: −33.0%, −53.4%, and −6.9% (case 1); −26.8%, −61.6%, and +2.5% (case 2); and −13.2%, −46.9%, and +5.8% (case 3). Accordingly, one patient lost 8.7% of weight as lean soft tissue, while two increased lean soft tissue. These findings highlight the potential for some individuals to preserve or even increase lean soft tissue during treatment with semaglutide or tirzepatide alongside supportive lifestyle strategies.

Overview

CoChat Summary

## TL;DR

This case series reports three patients using semaglutide or tirzepatide who lost substantial weight while preserving lean soft tissue, and two of the three increased lean soft tissue over follow-up. The authors suggest that consistent exercise, especially resistance training, plus adequate protein intake may have contributed.

## Key findings

  • Across the three cases, weight change, fat mass change, and lean soft tissue (LST) change were: −33.0%, −53.4%, and −6.9% (case 1); −26.8%, −61.6%, and +2.5% (case 2); and −13.2%, −46.9%, and +5.8% (case 3).
  • In terms of how much weight loss was attributable to LST, one patient lost 8.7% of weight as LST, while two increased LST.
  • The paper notes that in recent GLP-1/GLP-1/GIP trials, about 26%–40% of weight loss was due to lean soft tissue loss by DXA, and a network meta-analysis reported ~25% lean loss.
  • In these cases, the patients reported exercising 4–7 days/week, including resistance training 3–5 days/week, with typical protein intakes of 0.7–1.7 g/kg/day by body mass and 1.6–2.3 g/kg/day by fat-free mass.

## Methods

  • Design: Case series of three patients treated with semaglutide or tirzepatide and followed with serial DXA body composition measurements.
  • Sample/data: Patients came from a virtual health clinic; eligible participants had DXA results across obesity medication treatment plus records of nutrition and exercise habits. The sample included two females and one male, with baseline BMI 32.9–51.9 kg/m².
  • Main analysis: Descriptive comparison of DXA-derived body composition variables (body mass, BMI, LST, fat mass, and body fat %) from baseline to final assessment, alongside self-reported nutrition, supplementation, and exercise questionnaires.

## Limitations

  • The authors explicitly state this was “simple observation in a very small number of patients without a control group,” so causal inference is limited.
  • They state the study relied on self-reports for nutrition and physical activity, so recall bias and social expectation bias are possible.
  • They state the findings are not generalizable to all patients.
  • Evident from the text: DXA scans were done at different fee-for-service facilities across participants, which may add measurement variability, although each participant was scanned at the same facility over time.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1177/2050313x251388724

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Trajectory of body composition changes during treatment. Changes in body mass, fat mass, and lean soft tissue mass quantified by DXA are displayed for three patients. Each point indicates results from an individual DXA scan, and the weeks correspond to the duration since the baseline DXA assessment, which occurred near the beginning of treatment with semaglutide or tirzepatide. DXA: dual-energy X-ray absorptiometry.
Figure 1. Trajectory of body composition changes during treatment. Changes in body mass, fat mass, and lean soft tissue mass quantified by DXA are displayed for three patients. Each point indicates results from an individual DXA scan, and the weeks correspond to the duration since the baseline DXA assessment, which occurred near the beginning of treatment with semaglutide or tirzepatide. DXA: dual-energy X-ray absorptiometry.CC BY-NC · PubMed Central
Figure 2. DXA scan images. Images from DXA scans are displayed for case #2 at baseline (W0) and 10, 24, and 39 weeks later (W10, W24, and W39, respectively). DXA: dual-energy X-ray absorptiometry.
Figure 2. DXA scan images. Images from DXA scans are displayed for case #2 at baseline (W0) and 10, 24, and 39 weeks later (W10, W24, and W39, respectively). DXA: dual-energy X-ray absorptiometry.CC BY-NC · PubMed Central
Figure 3. Absolute and relative changes in body composition. Changes in BM, FM, and LST are displayed in absolute quantities (top row) and percent changes (bottom row). Changes were calculated from the first and last available dual-energy X-ray absorptiometry scans. BM: body mass; FM: fat mass; LST: lean soft tissue.
Figure 3. Absolute and relative changes in body composition. Changes in BM, FM, and LST are displayed in absolute quantities (top row) and percent changes (bottom row). Changes were calculated from the first and last available dual-energy X-ray absorptiometry scans. BM: body mass; FM: fat mass; LST: lean soft tissue.CC BY-NC · PubMed Central

Verification

Claims the paper makes

13 Valid · 0 Not valid · 4 Not checked · 29 Own results and interpretations

18 more claims

Create a free account to see all 46 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 17
  • It may state two separate claims as one. 16

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 27 references

Cited by

See all 15

Metadata

Authors
Tinsley, G. M., & Nadolsky, S.
Affiliations
  • Texas Tech University (US)
  • Vineyard Health, Holland, MI, USA
Corresponding author
Tinsley, Grant M.
Venue
SAGE Open Medical Case Reports
Published
2025-10
Volume
13
Pages
2050313X251388724-2050313X251388724
ISSN
2050-313X (ISSN-L)
OpenAlex
W4415260741
Cited by
15
References
27
Citations by year
2026: 14 · 2025: 1
FWCI
10.23
Type
journal article
Language
en
Open access
Licence
Locations
  • SAGE Open Medical Case Reports (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • OSF Preprints (OSF Preprints) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
Keywords
GLP-1 receptor agonists, semaglutide, tirzepatide, GIP/GLP-1 receptor agonist, weight loss, fat loss, resistance training, protein intake, fat-free mass, obesity, lifestyle intervention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series. https://app.cochat.ai/papers/10.1177/2050313x251388724
The paper
Tinsley, G. M., & Nadolsky, S. (2025). Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series. SAGE Open Medical Case Reports. https://doi.org/10.1177/2050313x251388724

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.